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Sildenafil augments the effect of inhaled nitric oxide for postoperative
pulmonary hypertensive crises
Andrew M. Atz, MD,a Amy K. Lefler, PharmD,b David L. Fairbrother, MD,a Walter E. Uber, PharmD,b and
Scott M. Bradley, MD,c Charleston, SC
Pulmonary hypertension remains a major complicationafter surgical correction of congenital heart disease. In-haled nitric oxide (NO) has been shown to reduce, butnot eliminate, potentially life-threatening episodic pul-
monary hypertensive crises.1 NO increases intracellular cyclic
guanosine monophosphate (cGMP), resulting in smooth muscle
vasodilation. Phosphodiesterase type 5 (PDE5) is responsible for
cGMP breakdown in lung tissue. We hypothesized that sildenafil
(Viagra; Pfizer Laboratories, New York, NY), a selective and
potent inhibitor of PDE5, may augment pulmonary vasodilation
with NO and reduce the risk of pulmonary hypertensive crises in
an at-risk postoperative patient.
Clinical Summary
A 9-month-old boy with congenital mitral stenosis underwent
supra-annular valve replacement with a 16-mm Carbomedics pros-
thesis (Sulzer Carbomedics, Austin, Tex). Postoperative support
included dopamine at 7 g  kg1  min1, milrinone at 0.75
g  kg1  min1, muscle relaxation with vecuronium at 0.1
mg  kg1  h1, sedation with fentanyl at 20 g  kg1  h1, and
controlled hyperventilation to a pH of greater than 7.5 and PO2 of
greater than 200 mm Hg. Left atrial pressure was 17 mm Hg,
pulmonary artery pressure was 74/44 mm Hg (mean, 54 mm Hg),
and systemic blood pressure was 91/38 mm Hg (mean, 57 mm
Hg). Inhaled NO given 2 hours after the operation produced a
selective 31% decrease in mean pulmonary artery pressure and
was continued at 20 ppm. Despite these medical maneuvers, the
infant had recurrent pulmonary hypertensive crises (abrupt in-
creases in pulmonary artery pressure accompanied by decreases in
systemic pressure and oxygen saturation) during endotracheal suc-
tioning, as well as other noxious stimuli. When this clinical status
persisted by postoperative day (POD) 4, an initial dose of sildenafil
(0.3 mg/kg) administered through a nasogastric tube showed an
augmented decrease in pulmonary artery pressures with no change
in heart rate, oxygen saturation, or systemic blood pressure (Figure
1). Sildenafil (0.3 mg/kg per dose) was then given every 4 hours.
No further pulmonary hypertensive events were provoked during
endotracheal suctioning or other stimuli. Vecuronium was stopped
on POD 7, and NO was weaned slowly: 20 ppm  4 days, 15
ppm  3 days, 10 ppm  1 day, 5 ppm  5 days, 3 ppm  1 day,
and weaned off over 4 hours on POD 15. Mean pulmonary artery
pressure was directly measured throughout and remained 60% to
70% of mean systemic blood pressure during this entire course. He
was extubated on POD 21, and sildenafil was discontinued on POD
22. No rebound phenomenon was seen over the next 36 hours, and
the pulmonary arterial catheter was removed on POD 23 with
discharge from the intensive care unit the following day.
Discussion
Previous reports describe the use of single doses of sildenafil to
augment and prolong the pulmonary vasodilator effect of NO in a
small cohort of adults during cardiac catheterization2 and to allow
successful discontinuation of inhaled NO in children after cardiac
surgery in whom NO withdrawal had previously failed.3 Pro-
longed therapy with sildenafil has been reported in one child
with primary pulmonary hypertension. After treatment failure
with NO and parenteral prostacyclin, sildenafil (2 mg/kg every 4
hours) resulted in decreased tricuspid regurgitation after 4 weeks
of therapy.4
The terminal half-life of sildenafil is approximately 4 hours,
and its elimination is primarily through a hepatic route.5 We
treated with sildenafil every 4 hours by using a 0.3 to 0.35 mg/kg
dose, as described previously.3 With direct continuous monitoring
of pulmonary artery and systemic blood pressure, we noted a
sustained therapeutic effect on pulmonary artery pressures and
observed no systemic hypotension with prolonged dosing at this
interval.
When added to NO, we found low-dose sildenafil to be a safe
and effective therapy for pulmonary hypertension, preventing fur-
ther pulmonary hypertensive crises associated with noxious stim-
uli. Sildenafil exhibited additive effects with NO on pulmonary
tone that were sustained during prolonged use and facilitated
weaning from NO. Sildenafil and other selective PDE5 inhibitors
with improved selectivity, shorter onset of action, and longer
half-life merit further carefully designed exploration for the treat-
ment of pulmonary hypertension. Until prospective studies inves-
tigate the pharmacokinetics, as well as other potential limitations
and unknown side effects, of this drug, extreme caution must be
taken in patients who may have high circulating levels of cGMP,
those receiving oral or intravenous nitrates, and those with hepatic
dysfunction.
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Figure 1. Continuous traces of heart rate, blood pressure (systolic, mean, and diastolic), and pulmonary artery
pressure (systolic, mean, and diastolic) recorded every minute. Despite treatment with NO at 20 ppm for 4 days,
the patient had persistently elevated pulmonary artery pressure. A 0.3 mg/kg dose of sildenafil given at the cursor
caused additional selective pulmonary vasodilation.
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